Clinical Trial Update: A Study to Compare Subcutaneous (SC) Versus Intravenous (IV) Administration of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial comparing subcutaneous versus intravenous administration of trastuzumab (Herceptin) in HER2-positive early breast cancer completed with results po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• HERCEPTIN (trastuzumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Breast Cancer | Phase 3 | Status: COMPLETED | Results posted: 2017-01-23